CYP19A1 rs1050567: Understanding Aromatase Gene Variation
The rs1050567 variant is a genetic change located within the CYP19A1 gene, which encodes the aromatase enzyme. This variant is studied for its potential influence on circulating estrogen levels and its association with cardiovascular risk profiles in postmenopausal women.
What each genotype means
Typical baseline estrogen profile
You carry two copies of the common A allele in the aromatase gene. Research indicates this genotype is generally associated with baseline circulating estrogen levels and typical timing of natural menopause, though individual variations are modest and influenced by multiple factors. Because overall evidence linking this specific single nucleotide polymorphism to reproductive endpoints remains limited, it should not be viewed as predictive.
Carried by approximately 35% to 40% of individuals of European descent and is prevalent across many global populations.
Intermediate estrogen profile
You carry one copy of the G allele alongside one copy of the A allele in CYP19A1. Genetic studies have noted modest, inconsistent associations between this minor allele and minor fluctuations in circulating estrogen or subtle shifts in menopausal timing. The overall clinical impact of a single G allele is considered minor and remains inconclusive across diverse ancestry groups.
Carried by roughly 45% to 50% of people of European ancestry and is common worldwide.
Minor allele homozygote
You carry two copies of the G allele in the CYP19A1 gene. Some association studies have evaluated this genotype for small differences in circulating postmenopausal hormone levels and natural menopausal timing, but the evidence remains limited and mixed. This genetic finding does not diagnose any endocrine condition or predict precise menopausal onset.
Present in about 15% to 20% of individuals of European ancestry and occurs at varying frequencies globally.
What is the rs1050567 Variant?
The rs1050567 variant is a single-nucleotide polymorphism (SNP) found within the CYP19A1 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This specific variant is located in a region of the genome that influences how the body produces and regulates aromatase. Because it is a common variant, it is frequently included in studies examining how genetic differences contribute to variations in hormone levels between people. Researchers track these variations to understand if they correlate with specific physiological traits, such as the timing of menopause or the body's response to hormonal changes later in life. It is important to note that while this variant is a subject of scientific interest, it is just one of many factors that influence complex biological processes like hormone synthesis.
The Role of the CYP19A1 Gene
The CYP19A1 gene provides instructions for making an enzyme called aromatase. Aromatase is essential for the body's endocrine system because it catalyzes the final step in the biosynthesis of estrogens, converting androgens (such as testosterone and androstenedione) into estrogens (such as estradiol and estrone). This process occurs in various tissues, including the ovaries, adipose tissue, and the brain. By regulating the balance between androgens and estrogens, aromatase plays a critical role in reproductive health, bone density maintenance, and cardiovascular function. Because the enzyme is so central to hormone production, variations in the CYP19A1 gene can lead to subtle differences in how much estrogen an individual produces. Understanding these genetic differences helps scientists map the complex pathways that maintain hormonal homeostasis throughout different stages of life.
Research Associations and Evidence Strength
Research into rs1050567 and related variants in the CYP19A1 gene has primarily focused on their association with circulating estrogen levels. Studies have observed that certain genetic profiles at this locus may correlate with measurable differences in hormone concentrations, particularly in postmenopausal women. Some research has further explored whether these hormonal differences influence cardiovascular risk markers or the timing of menopause. However, the evidence for these associations is currently considered limited. While some studies suggest a statistical link between specific genotypes and health outcomes, others have found no significant impact, or have noted that the effect size is too small to be clinically predictive on its own. Because these associations are often influenced by environmental factors, lifestyle, and other genetic markers, the findings remain a subject of ongoing investigation rather than established clinical fact.
Population Frequency
The rs1050567 variant is considered common across most global populations. This means that a significant portion of the general population carries one or more copies of the variant alleles. Because it is a common polymorphism, it is frequently observed in large-scale genomic studies, allowing researchers to compare its frequency across different ancestral groups. While the specific distribution of genotypes may vary slightly between populations, the variant is not restricted to any single ethnic or geographic group. This widespread presence is typical for many SNPs that have been maintained in the human genome over time. Understanding its prevalence helps scientists ensure that research findings are representative of diverse groups, though it also highlights the need for caution when interpreting results that may be specific to certain cohorts.
Interpreting Your Genetic Information
If you have information about your genotype for rs1050567, it is important to view it within the context of your overall health. Genetic variants are rarely the sole cause of health outcomes; they typically interact with diet, exercise, age, and other environmental factors. You cannot use this information to diagnose a condition or predict your future health with certainty. If you are concerned about your hormone levels, cardiovascular health, or menopause symptoms, the most effective approach is to consult with a healthcare professional. They can evaluate your clinical history, perform necessary blood tests, and provide guidance based on your individual needs. Never make changes to your health regimen or medication based on genetic data alone without first discussing it with your doctor or a qualified pharmacist.
How common is this variant?
The rs1050567 variant is common in most populations, with its genotypes appearing frequently across diverse ancestral groups.
Frequently asked questions
Does this variant mean I will have early menopause?
No. While some research investigates the link between CYP19A1 variants and the timing of menopause, this SNP is not a diagnostic tool. Menopause timing is a complex trait influenced by many genetic and environmental factors.
Can I use this result to change my hormone therapy?
No. You should never adjust hormone therapy or any other medication based on genetic test results without consulting your clinician. Always discuss your health goals and any genetic information with your doctor.
Is this variant associated with breast cancer risk?
Research on this topic has been mixed. Some studies have looked for associations between CYP19A1 variants and breast cancer risk, but results have often been inconclusive or shown no significant clinical impact.
What should I do if I am worried about my estrogen levels?
If you have concerns about your hormone levels, you should schedule an appointment with your healthcare provider. They can order appropriate blood tests to measure your actual hormone levels and provide medical advice.
Sources & further reading
Educational information only, last refreshed 10/25/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1050567?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP19A1
This regulatory variant in the aromatase gene is associated with circulating estradiol levels and the timing of natural menopause.
Pathogenic variant causing aromatase deficiency characterized by female pseudohermaphroditism, maternal virilization during pregnancy, and absent pubertal development.
Intronic variant in the CYP19A1 gene associated with circulating estradiol and follicle-stimulating hormone (FSH) levels in men.
This variant in the aromatase gene is associated with variations in sex hormone levels and potential risk modulation for hormone-dependent reproductive cancers.
Affects aromatase activity, influencing efficacy and toxicity in hormone-sensitive cancer treatments.
Polymorphism in the aromatase gene (CYP19A1) associated with circulating estradiol levels and bone mineral density.